133 related articles for article (PubMed ID: 25354264)
21. ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 Feb; 140(2):157-8. PubMed ID: 23395504
[No Abstract] [Full Text] [Related]
22. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
23. TNF-α inhibitor (adalimumab) induced psoriasis: a case report.
Al-Mutairi A; Elkashlan M; Al-Fayed HM; Swayed M
Australas J Dermatol; 2012 May; 53(2):157. PubMed ID: 22571571
[No Abstract] [Full Text] [Related]
24. [1/2 The anti-TNF alpha drugs].
Medjoub M; Limat S; Woronoff-Lemsi MC
Soins; 2007 Oct; (719):59-61. PubMed ID: 18020248
[No Abstract] [Full Text] [Related]
25. Advertisements for TNF Inhibitors.
Med Lett Drugs Ther; 2008 Nov; 50(1299):89. PubMed ID: 19008788
[No Abstract] [Full Text] [Related]
26. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
[TBL] [Abstract][Full Text] [Related]
27. [What is the risk of malignancies associated with anti-TNF therapy?].
Jonville-Béra AP; Lorette G
Presse Med; 2009 Sep; 38(9):1209-10. PubMed ID: 19324517
[No Abstract] [Full Text] [Related]
28. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
29. [Alopecia areata during anti-TNF alpha therapy: Nine cases].
Le Bidre E; Chaby G; Martin L; Perrussel M; Sassolas B; Sigal ML; Kaassis C; Lespessailles E; Nseir A; Estève E
Ann Dermatol Venereol; 2011; 138(4):285-93. PubMed ID: 21497255
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
[No Abstract] [Full Text] [Related]
31. Autoimmune hepatitis triggered by adalimumab and allergic reactions after various anti-TNFα therapy agents in a patient with rheumatoid arthritis.
Petríková J; Jarčuška P; Svajdler M; Pella D; Macejová Z
Isr Med Assoc J; 2015 Apr; 17(4):256-8. PubMed ID: 26040057
[No Abstract] [Full Text] [Related]
32. Cutaneous pseudolymphoma caused by tumor necrosis factor-α inhibitors was not induced by ustekinumab.
Imafuku S; Tatsukawa R; Ito K; Nakayama J
J Dermatol; 2012 Dec; 39(12):1070. PubMed ID: 22698067
[No Abstract] [Full Text] [Related]
33. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
[TBL] [Abstract][Full Text] [Related]
34. Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee.
Kavanagh PM; Gilmartin JJ; O'Donnell J; O'Flanagan D
Ir Med J; 2008 Jan; 101(1):6-7. PubMed ID: 18369014
[No Abstract] [Full Text] [Related]
35. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy.
Borrás-Blasco J; Navarro-Ruiz A; Borrás C; Casterá E
South Med J; 2009 Nov; 102(11):1133-40. PubMed ID: 19864977
[TBL] [Abstract][Full Text] [Related]
36. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
37. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
[TBL] [Abstract][Full Text] [Related]
38. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
39. Infections associated with tumor necrosis factor-alpha antagonists.
Rychly DJ; DiPiro JT
Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
[TBL] [Abstract][Full Text] [Related]
40. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
